Swedish Orphan Biovitrum Release: Interim Report, January -September 2012

Published: Oct 30, 2012

Geoffrey McDonough, CEO: "The third quarter continued to demonstrate solid underlying growth in product sales and an improvement of the gross margin in line with our expectations. In September we reported positive top-line results from our factor IX phase III program with Biogen Idec for the development of a long-lasting recombinant coagulation factor for hemophilia B. In addition we were granted priority review by the FDA for our application for Kineret® for the NOMID indication with an expected approval date in late December 2012. We also continued to strengthen the Partner Product portfolio through the extension and expansion of several existing partnerships."

Back to news